NASDAQ:SCLX Scilex (SCLX) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free SCLX Stock Alerts $0.85 -0.07 (-7.58%) (As of 04/30/2024 ET) Add Compare Share Share Today's Range$0.82▼$0.9250-Day Range$0.85▼$2.4252-Week Range$0.80▼$8.37Volume698,332 shsAverage Volume998,921 shsMarket Capitalization$141.79 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Scilex alerts: Email Address Scilex MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside837.6% Upside$8.00 Price TargetShort InterestBearish7.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector652nd out of 918 stocksBiological Products, Except Diagnostic Industry105th out of 151 stocks 3.5 Analyst's Opinion Consensus RatingScilex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageScilex has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.13% of the float of Scilex has been sold short.Short Interest Ratio / Days to CoverScilex has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Scilex has recently increased by 11.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldScilex does not currently pay a dividend.Dividend GrowthScilex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCLX. Previous Next 2.9 News and Social Media Coverage News SentimentScilex has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Scilex this week, compared to 2 articles on an average week.Search Interest5 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows60 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 5% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scilex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.73% of the stock of Scilex is held by insiders.Percentage Held by Institutions69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Scilex are expected to grow in the coming year, from ($0.51) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scilex is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scilex is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…For the full story, click here. About Scilex Stock (NASDAQ:SCLX)Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Read More SCLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCLX Stock News HeadlinesApril 26, 2024 | investing.comScilex secures $15 million in registered direct offeringApril 25, 2024 | globenewswire.comScilex Holding Company Announces Closing of $15 Million Registered Direct OfferingMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…April 25, 2024 | americanbankingnews.comContrasting Sangamo Therapeutics (NASDAQ:SGMO) and Scilex (NASDAQ:SCLX)April 24, 2024 | globenewswire.comScilex Holding Company Announces $15 Million Registered Direct OfferingApril 16, 2024 | msn.comScilex to reduce R&D expenses in 2024, comments on actions post Change Healthcare cyberattackApril 16, 2024 | globenewswire.comScilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative ExpensesApril 9, 2024 | globenewswire.comScilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing PoolMay 1, 2024 | Porter & Company (Ad)The biggest energy story ever? Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…March 27, 2024 | globenewswire.comScilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a DividendMarch 21, 2024 | globenewswire.comScilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured PatientsMarch 20, 2024 | globenewswire.comScilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is NeededMarch 20, 2024 | globenewswire.comScilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®March 19, 2024 | msn.comScilex Holding repays the remaining balance of convertible debenturesMarch 19, 2024 | globenewswire.comScilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationMarch 18, 2024 | globenewswire.comScilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in CanadaMarch 16, 2024 | finance.yahoo.comSCLX Apr 2024 2.000 putMarch 16, 2024 | finance.yahoo.comSCLX Apr 2024 1.000 putMarch 15, 2024 | globenewswire.comScilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.March 15, 2024 | markets.businessinsider.comScilex Pharma Enters Definitive Mutual Release And Settlement Agreement With VirpaxMarch 15, 2024 | finance.yahoo.comScilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and SettlementMarch 15, 2024 | globenewswire.comScilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and SettlementMarch 14, 2024 | finance.yahoo.comScilex Holding Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 12, 2024 | finance.yahoo.comSCLX Grows Revenue and Boosts MarketingMarch 9, 2024 | finance.yahoo.comScilex Holding Company (NASDAQ:SCLX) most popular amongst private companies who own 57% of the shares, institutions hold 25%March 6, 2024 | msn.comSCLX Continues to Make StridesMarch 5, 2024 | globenewswire.comScilex Holding Company Announces Closing of $10 Million Bought Deal OfferingSee More Headlines Receive SCLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/30/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SCLX CUSIPN/A CIK1820190 Webwww.scilexholding.com Phone650-516-4310FaxN/AEmployees105Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$12.00 Low Stock Price Target$4.00 Potential Upside/Downside+837.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-114,330,000.00 Net Margins-244.60% Pretax Margin-244.57% Return on EquityN/A Return on Assets-112.17% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.17 Sales & Book Value Annual Sales$46.74 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.78Miscellaneous Outstanding Shares166,190,000Free Float151,682,000Market Cap$141.79 million OptionableOptionable Beta0.69 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Henry H. Ji Ph.D. (Age 60)Executive Chairman Comp: $885.43kMr. Stephen Ma (Age 51)Senior VP, CFO & Corporate Secretary Comp: $708.78kMr. Jaisim Shah (Age 64)President, CEO & Director Comp: $785.73kDr. Suketu D. Desai Ph.D. (Age 58)CTO & Senior VP Ms. Gigi DeGuzmanExecutive Director of Administrative Operations & Head of Human ResourcesMr. Steven F. Lincoln J.D.General Counsel & Chief Compliance OfficerMr. Sumant RajendranExecutive Director of MarketingMike CiaffiNational Sales DirectorMr. Suresh K. Khemani (Age 64)Senior VP & Chief Commercial Officer Comp: $456.82kDr. Dmitri V. Lissin M.D. (Age 64)Senior VP & Chief Medical Officer Comp: $528.83kMore ExecutivesKey CompetitorsCellectisNASDAQ:CLLSMolecular PartnersNASDAQ:MOLNCardiol TherapeuticsNASDAQ:CRDLDBV TechnologiesNASDAQ:DBVTVaxartNASDAQ:VXRTView All CompetitorsInstitutional OwnershipCannon Global Investment Management LLCBought 25,000 shares on 4/17/2024Ownership: 0.015%Collective Family Office LLCBought 8,918 shares on 4/9/2024Ownership: 0.013%Tower Research Capital LLC TRC Sold 98,480 shares on 2/13/2024Ownership: 0.013%Focus Financial Network Inc. ADVBought 28,257 shares on 2/12/2024Ownership: 0.018%Apollon Wealth Management LLCSold 13,900 shares on 2/6/2024Ownership: 0.023%View All Institutional Transactions SCLX Stock Analysis - Frequently Asked Questions Should I buy or sell Scilex stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCLX shares. View SCLX analyst ratings or view top-rated stocks. What is Scilex's stock price target for 2024? 2 brokerages have issued 1-year target prices for Scilex's shares. Their SCLX share price targets range from $4.00 to $12.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 837.6% from the stock's current price. View analysts price targets for SCLX or view top-rated stocks among Wall Street analysts. How have SCLX shares performed in 2024? Scilex's stock was trading at $2.04 at the start of the year. Since then, SCLX stock has decreased by 58.2% and is now trading at $0.8532. View the best growth stocks for 2024 here. When is Scilex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our SCLX earnings forecast. How were Scilex's earnings last quarter? Scilex Holding (NASDAQ:SCLX) issued its earnings results on Monday, March, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. The firm earned $13.46 million during the quarter, compared to analyst estimates of $11.43 million. What ETFs hold Scilex's stock? ETFs with the largest weight of Scilex (NASDAQ:SCLX) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM) and Invesco PureBeta MSCI USA Small Cap ETF (PBSM).Nationwide Russell 2000 Risk-Managed Income ETF (NTKI). Who are Scilex's major shareholders? Scilex's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannon Global Investment Management LLC (0.02%) and Collective Family Office LLC (0.01%). How do I buy shares of Scilex? Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCLX) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersElon’s New A.I. Device is About to Shock the WorldInvestorPlaceAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTracker#1 election stockPorter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
